|  |  |
| --- | --- |
|  | **Serious Adverse Event Reporting Format (Biomedical Health Research)**  **National Institute of Mental Health & Neuro Sciences**    **EC Ref. No*.(****for office use):* |

|  |
| --- |
| Title of study:  Principal Investigator (Name, Designation and Affiliation) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Participant details : | | | |
| Initials and ID | Age at the time of event | Gender  Male  Female | Weight:       (Kgs)  Height:      (cms) |
|  | Suspected SAE diagnosis: | | | |
|  | Date of onset of SAE: Click here to enter a date. | | Describe the event*19*: | |
| Date of reporting SAE: Click here to enter a date. | |
|  | Details of suspected intervention causing SAE*20* | | | |
|  | Report type: Initial  Follow-up  Final  If Follow-up report, state date of Initial report Click here to enter a date. | | | |
|  | Have any similar SAE occurred previously in this study? If yes, please provide details. Yes  No | | | |
|  |  | | | |
|  | In case of a multi-centric study, have any of the other study sites reported similar SAEs (Please list number of cases with details if available). | | | |
|  | |  | | --- | | Tick whichever is applicable for the SAE: *(Kindly note that this refers to the Intervention being evaluated and NOT disease process)* | | 1. Expected event  Unexpected event   *19Duration, setting, site, signs, symptoms, severity, criteria for regarding the event serious*  *20Refers to research intervention including basic, applied and operational research or clinical research, except for investigational new drugs. If it is an academic clinical trial, mention name, indications, dosage, form and strength of the drug(s)* | | |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | Hopitalization |  | Increased Hospital Stay |  | Death |  | Congenital anomaly/birth defect |  | | Persistent or significant disability/incapacity |  | Event requiring intervention (surgical or medical) to prevent SAE |  | Event which poses threat to life |  | Others |  |   B.    In case of death, state probable cause of death: | | |  | | --- | | C. No permanent/significant functional/cosmetic impairment | | Permanent/significant functional/cosmetic impairment | | Not Applicable | | | | | |
| 1. g | Describe the medical management provided for adverse reaction (if any) to the research participants. (include the information on who paid, how much was paid and to whom) | | | |
|  | Proide details of compensation provided/ to be provided to participants (include the information on who paid, how much was paid and to whom) | | | |
|  | Outcome of SAE   |  |  |  |  | | --- | --- | --- | --- | | Fatal |  | Recovered |  | | Continuing |  | Unknown |  | | Recovering |  | others(*specify*) |  | | | | |
|  | Provide any other relevant information to that can facilitate assessment of the case such as medical history | | | |
| 1. provide | Provide details about PI’s final assessment of SAE relatedness to trial. | | | |

Signature of PI:  Click here to enter a date.